Neurosciences News

Patients treated with satralizumab as monotherapy were at less risk for neuromyelitis optica spectrum disorder relapse compared with patients treated with placebo, according to a study.

People with Parkinson’s disease have a higher prevalence of ophthalmologic symptoms than those without the disease, according to research published in Neurology, the medical journal of the American Academy of Neurology.

Neuro-ophthalmologic function is affected by subconcussive head impacts which may affect individuals participating in contact sports, according to a randomized clinical trial.

KOLOA, Hawaii — At Hawaiian Eye 2020, Andrew G. Lee, MD, discusses how ophthalmologists need to be able to identify neuromyelitis optica, or NMO, and shares differentiating features of the condition.

The FDA has granted breakthrough device designation to the RightEye Vision System, an oculomotor test to help diagnose Parkinson’s disease, RightEye LLC announced in a press release.

Satralizumab added to immunosuppressant treatment may reduce relapse in some cases of neuromyelitis optica spectrum disorder.

A 71-year-old man was referred by his usual ophthalmologist to the neuro-ophthalmology clinic at Tufts Medical Center for bilateral decreased vision associated with bilateral optic disc edema.

The FDA has accepted a biologics license application for satralizumab for the treatment of neuromyelitis optica spectrum disorder, Genentech/Roche announced in a press release.

Healio.com/OSN is the online home of Ocular Surgery News. In addition to housing the online version of OSN, Healio/OSN creates daily news, meeting news coverage, executive summaries of journal articles, perspectives, videos, blogs and podcasts. With the increasing importance of Healio as the online presence of Ocular Surgery News and the continuous growth that is taking place online, we decided it was a good time to boost the Healio/OSN editorial board presence in the ophthalmic community.

Satralizumab monotherapy achieved a 55% reduction in the risk for relapses compared with placebo in patients with neuromyelitis optica spectrum disorder, according to a press release from Genentech.